Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:aims_to |
treat cardiovascular diseases
|
| gptkbp:ceo |
Jean-Louis Dasseux
|
| gptkbp:clinical_trial |
Phase 3 trials
|
| gptkbp:develops |
Cerenis Therapeutics' lead product
|
| gptkbp:focuses_on |
lipid therapies
|
| gptkbp:founded |
gptkb:2005
|
| gptkbp:funding |
gptkb:venture_capital
|
| gptkbp:headquarters |
gptkb:Toulouse,_France
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cerenis Therapeutics
|
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:bfsParent |
gptkb:Johnson_&_Johnson_Services,_Inc.
|
| gptkbp:bfsLayer |
6
|